Combined carboplatin plus bleomycin and conventional radiotherapy for advanced carcinomas of the head and neck

M. C. Espinoza-Jacobs, M. Suntharalingam, Mario Eisenberger, Victoria Sinibaldi, O. M. Salazar

Research output: Contribution to journalArticle

Abstract

In a previous study, we reported a 72% response rate (CR = 52%) in patients with unresectable head and neck (H and N) carcinomas treated with simultaneous carboplatin (CBDCA) and radiotherapy (RT). Bleomycin (Bleo), a known radio-sensitizing agent, has been shown to increase response rates when given together with RT in similar patients. To explore the nonoverlapping toxicities of these two agents, we combined i.v. CBDCA (100 mg/m2/week), Bleo (5 units on day 1 and 4/weekly) and standard doses of RT in patients with unresectable H and N carcinomas. Chemotherapy (CT) was continued until completion of RT. Twenty-three (13 males, 10 females) previously untreated patients with stage IV squamous cell carcinoma of the H and N were treated at the University of Maryland Medical Center: 61% had oropharyngeal cancers; 26%, hypopharynx; 9%, oral cavity; and 4%, an unknown primary. Moderate to severe mucositis developed in 90%, which required RT interruptions of ap to 3 weeks. After a median follow-up (FU) of 18 months, 35% achieved a complete response (CR) and 65% died from progressive disease. These preliminary data suggest that the addition of Bleo increases mucosal toxicity substantially and, while a moderate response rate was observed, it is unlikely that the CR rate will be higher than CBDCA/RT, which was also better tolerated and hence more suitable to multimodal approaches.

Original languageEnglish (US)
Pages (from-to)52-55
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume18
Issue number1
StatePublished - 1995
Externally publishedYes

Fingerprint

Carboplatin
Bleomycin
Neck
Radiotherapy
Head
Carcinoma
Oropharyngeal Neoplasms
Hypopharynx
Mucositis
Radio
Mouth
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combined carboplatin plus bleomycin and conventional radiotherapy for advanced carcinomas of the head and neck. / Espinoza-Jacobs, M. C.; Suntharalingam, M.; Eisenberger, Mario; Sinibaldi, Victoria; Salazar, O. M.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 18, No. 1, 1995, p. 52-55.

Research output: Contribution to journalArticle

@article{bcf47ae27d10415b9980d8e61c25db9a,
title = "Combined carboplatin plus bleomycin and conventional radiotherapy for advanced carcinomas of the head and neck",
abstract = "In a previous study, we reported a 72{\%} response rate (CR = 52{\%}) in patients with unresectable head and neck (H and N) carcinomas treated with simultaneous carboplatin (CBDCA) and radiotherapy (RT). Bleomycin (Bleo), a known radio-sensitizing agent, has been shown to increase response rates when given together with RT in similar patients. To explore the nonoverlapping toxicities of these two agents, we combined i.v. CBDCA (100 mg/m2/week), Bleo (5 units on day 1 and 4/weekly) and standard doses of RT in patients with unresectable H and N carcinomas. Chemotherapy (CT) was continued until completion of RT. Twenty-three (13 males, 10 females) previously untreated patients with stage IV squamous cell carcinoma of the H and N were treated at the University of Maryland Medical Center: 61{\%} had oropharyngeal cancers; 26{\%}, hypopharynx; 9{\%}, oral cavity; and 4{\%}, an unknown primary. Moderate to severe mucositis developed in 90{\%}, which required RT interruptions of ap to 3 weeks. After a median follow-up (FU) of 18 months, 35{\%} achieved a complete response (CR) and 65{\%} died from progressive disease. These preliminary data suggest that the addition of Bleo increases mucosal toxicity substantially and, while a moderate response rate was observed, it is unlikely that the CR rate will be higher than CBDCA/RT, which was also better tolerated and hence more suitable to multimodal approaches.",
author = "Espinoza-Jacobs, {M. C.} and M. Suntharalingam and Mario Eisenberger and Victoria Sinibaldi and Salazar, {O. M.}",
year = "1995",
language = "English (US)",
volume = "18",
pages = "52--55",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Combined carboplatin plus bleomycin and conventional radiotherapy for advanced carcinomas of the head and neck

AU - Espinoza-Jacobs, M. C.

AU - Suntharalingam, M.

AU - Eisenberger, Mario

AU - Sinibaldi, Victoria

AU - Salazar, O. M.

PY - 1995

Y1 - 1995

N2 - In a previous study, we reported a 72% response rate (CR = 52%) in patients with unresectable head and neck (H and N) carcinomas treated with simultaneous carboplatin (CBDCA) and radiotherapy (RT). Bleomycin (Bleo), a known radio-sensitizing agent, has been shown to increase response rates when given together with RT in similar patients. To explore the nonoverlapping toxicities of these two agents, we combined i.v. CBDCA (100 mg/m2/week), Bleo (5 units on day 1 and 4/weekly) and standard doses of RT in patients with unresectable H and N carcinomas. Chemotherapy (CT) was continued until completion of RT. Twenty-three (13 males, 10 females) previously untreated patients with stage IV squamous cell carcinoma of the H and N were treated at the University of Maryland Medical Center: 61% had oropharyngeal cancers; 26%, hypopharynx; 9%, oral cavity; and 4%, an unknown primary. Moderate to severe mucositis developed in 90%, which required RT interruptions of ap to 3 weeks. After a median follow-up (FU) of 18 months, 35% achieved a complete response (CR) and 65% died from progressive disease. These preliminary data suggest that the addition of Bleo increases mucosal toxicity substantially and, while a moderate response rate was observed, it is unlikely that the CR rate will be higher than CBDCA/RT, which was also better tolerated and hence more suitable to multimodal approaches.

AB - In a previous study, we reported a 72% response rate (CR = 52%) in patients with unresectable head and neck (H and N) carcinomas treated with simultaneous carboplatin (CBDCA) and radiotherapy (RT). Bleomycin (Bleo), a known radio-sensitizing agent, has been shown to increase response rates when given together with RT in similar patients. To explore the nonoverlapping toxicities of these two agents, we combined i.v. CBDCA (100 mg/m2/week), Bleo (5 units on day 1 and 4/weekly) and standard doses of RT in patients with unresectable H and N carcinomas. Chemotherapy (CT) was continued until completion of RT. Twenty-three (13 males, 10 females) previously untreated patients with stage IV squamous cell carcinoma of the H and N were treated at the University of Maryland Medical Center: 61% had oropharyngeal cancers; 26%, hypopharynx; 9%, oral cavity; and 4%, an unknown primary. Moderate to severe mucositis developed in 90%, which required RT interruptions of ap to 3 weeks. After a median follow-up (FU) of 18 months, 35% achieved a complete response (CR) and 65% died from progressive disease. These preliminary data suggest that the addition of Bleo increases mucosal toxicity substantially and, while a moderate response rate was observed, it is unlikely that the CR rate will be higher than CBDCA/RT, which was also better tolerated and hence more suitable to multimodal approaches.

UR - http://www.scopus.com/inward/record.url?scp=0028947815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028947815&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 52

EP - 55

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -